Nymox Pharmaceutical Corporation news

   Watch this stock
Showing stories 1 - 10 of about 14   

Articles published

NYMX 4.94 -0.01 (-0.20%)
price chart
Investors Alert: Nymox Pharmaceutical Corporation (NASDAQ:NYMX), Omeros ...
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced its financial results for the second quarter of 2014. Nymox reported net losses of $820,272, or $0.02 per share, for the quarter and $3,413,088, or $0.10 per share, for the six months ended ...
Hot Stocks : Micrel Inc. (NASDAQ:MCRL), Harmonic Inc. (NASDAQ:HLIT ...
On Friday shares of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) ended up at $5.43. This year Company's Earnings per Share (EPS) growth is 39.10%.
Press Release Issued Under the Early Warning System/Sale of Shares of Nymox ...
Paul Averback MD announces today that he has sold in a private transaction for financial planning purposes 470,600 common shares of Nymox Pharmaceutical Corporation ("Nymox") for a total consideration of US $2,400,000 ($2,622,240 CDN). This sale ...
Today's Stocks : TrueCar (NASDAQ:TRUE), Colfax (NYSE:CFX), Nymox ...
On JULY 22, Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce new positive efficacy data for U.S. Study NX02-0022, the Company's repeat injection study of NX-1207 for BPH.
Nymox Reports Second Quarter 2014 Financial Results
Nymox Pharmaceutical Corporation NYMX, -0.19% announced today its financial results for the second quarter of 2014. Nymox reported net losses of $820,272, or $0.02 per share, for the quarter and $3,413,088, or $0.10 per share, for the six months ended ...
Related articles »  
Active Watch List : Cisco Systems (NASDAQ:CSCO), Aeropostale (NYSE:ARO ...
Aeropostale, Inc. (NYSE:ARO) price to sales (P/S) ratio is 0.15. On AUG 11, Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced its financial results for the second quarter of 2014.
Why Making Dramatic Moves : Xerox Corporation (NYSE:XRX), PharMerica ...
On 11 AUG Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced its financial results for the second quarter of 2014. Nymox reported net losses of $820,272, or $0.02 per share, for the quarter and $3,413,088, or $0.10 per share, for the six months ...
Related articles »  
Urology Product Preview: Testosterone agent meets efficacy endpoint in phase ...
Nymox Pharmaceutical Corp. announced positive efficacy data from its phase III NX02-022 repeat injection study of NX-1207 for BPH.